Abstract
After extensive investigation in preclinical studies and recent clinical trials, gene therapy has been established as a potential method to induce therapeutic angiogenesis in ischemic myocardial and limb disease. Advancements in viral and nonviral vector technology including cell-based gene transfer will continue to improve transgene transmission and expression efficiency. An alternative strategy to the use of transgenes encoding angiogenic growth factors is therapy based on transcription factors such as hypoxia-inducible factor-1α (HIF-1α) that regulate the expression of multiple angiogenic genes. Further understanding of the underlying biology of neovascularization is needed to determine the ability of growth factors to induce functionally significant angiogenesis in patients with atherosclerotic disease and associated comorbid conditions including endothelial dysfunction, which may inhibit blood vessel growth. The safety and tolerability of therapeutic angiogenesis by gene transfer has been demonstrated in phase I clinical trials. However, limited evidence of efficacy resulted from early phase II studies of angiogenic gene therapy for ischemic myocardial and limb disease. The utility of therapeutic angiogenesis by gene transfer as a treatment option for ischemic cardiovascular disease will be determined by adequately powered, randomized, placebo-controlled phase II and III clinical trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Laham R, Simons M . Growth factor therapy in ischemic heart disease. In: Rubanyi G (ed). Angiogenesis in Health and Disease. Marcel Decker: New York, 2000, pp 451–475.
Carmeliet P . Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389–395.
Laham RJ, Simons M, Sellke F . Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med 2001; 52: 485–502.
Laham RJ, Mannam A, Post MJ, Sellke F . Gene transfer to induce angiogenesis in myocardial and limb ischaemia. Expert Opin Biol Ther 2001; 1: 985–994.
Simons M et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000; 102: E73–E86.
Qian HS et al. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ Res 2001; 88: 911–917.
Maione D et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001; 98: 5986–5991.
Hofman CR et al. Efficient in vivo gene transfer by PCR amplified fragment with reduced inflammatory activity. Gene Therapy 2001; 8: 71–74.
Norman J et al. Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Therapy 2000; 7: 1425–1430.
Lawrie A et al. Microbubble-enhanced ultrasound for vascular gene delivery. Gene Therapy 2000; 7: 2023–2027.
Taniyama Y et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Therapy 2002; 9: 372–380.
Taniyama Y et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002; 105: 1233–1239.
Simberg D et al. Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. J Biol Chem 2001; 276: 47453–47459.
Gowdak LH et al. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J Vasc Surg 2000; 32: 343–352.
Aoki M et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Therapy 2000; 7: 417–427.
Powell C, Shansky J, Del Tatto M, Vandenburgh HH . Bioartificial muscles in gene therapy. Methods Mol Med 2002; 69: 219–231.
Lu Y et al. Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis. Circulation 2001; 104: 594–599.
Suzuki K et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001; 104: I207–I212.
Iwaguro H et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105: 732–738.
Khan TA, Sellke FW, Laham RJ . Therapeutic angiogenesis for coronary artery disease. Curr Treat Options Cardiovasc Med 2002; 4: 65–74.
Faries PL, Pomposelli Jr FB, Quist WC, LoGerfo FW . Assessing the role of gene therapy in the treatment of vascular disease. Ann Vasc Surg 2000; 14: 181–188.
Li J et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000; 6: 49–55.
Byun J et al. Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J Mol Cell Cardiol 2001; 33: 295–305.
Shimpo M et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res 2002; 53: 993–1001.
Taniyama Y et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Therapy 2001; 8: 181–189.
Onimaru M et al. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 2002; 91: 923–930.
Baumgartner I et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132: 880–884.
Makinen K et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127–133.
Lee LY et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000; 69: 14–23; discussion 23–14.
Su H, Lu R, Kan YW . Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA 2000; 97: 13801–13806.
Vincent KA et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102: 2255–2261.
Shyu KG et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002; 54: 576–583.
Laham RJ et al. Longevity of the placebo effect in patients enrolled in angiogenesis and laser myocardial revascularization trials. J Am Coll Cardiol 2002; 39: 11A.
Sarkar N et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease – 12-month follow-up: angiogenic gene therapy. J Intern Med 2001; 250: 373–381.
Vale PR et al. Effective gene transfer of phVEGF-2 for therapeutic angiogenesis in chronic myocardial ischemia as assessed by NOGATM left ventricular electromechanical mapping. Circulation 2000; 102: II689.
Vale PR et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138–2143.
Losordo DW et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012–2018.
Huwer H et al. Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease. Eur J Cardiothorac Surg 2001; 20: 1128–1134.
Grines CL et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291–1297.
Ruel M et al. Inhibited angiogenic response to surgical FGF-2 protein therapy in a swine model of endothelial dysfunction. Circulation (in press).
Dor Y et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002; 21: 1939–1947.
Ruel M et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002; 124: 28–34.
Acknowledgements
Supported in part by NIH Grants MO1-RR01032 and HL63609 (RJL), and HL46716 and HL69024 (FWS). Dr Khan is supported by an NIH Individual National Research Service Award, HL69651-01.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Khan, T., Sellke, F. & Laham, R. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 10, 285–291 (2003). https://doi.org/10.1038/sj.gt.3301969
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301969
Keywords
This article is cited by
-
Angiogenic potency evaluation of cell therapy candidates by a novel application of the in vitro aortic ring assay
Stem Cell Research & Therapy (2017)
-
Angiogenic growth factors in myocardial infarction: a critical appraisal
Heart Failure Reviews (2017)
-
Acceleration of bone-defect repair by using A-W MGC loaded with BMP2 and triple point-mutant HIF1α-expressing BMSCs
Journal of Orthopaedic Surgery and Research (2015)
-
Triple Point-Mutants of Hypoxia-Inducible Factor-1α Accelerate In Vivo Angiogenesis in Bone Defect Regions
Cell Biochemistry and Biophysics (2013)
-
RETRACTED ARTICLE: A novel method of augmenting gene expression and angiogenesis in the normal and ischemic canine myocardium
Heart and Vessels (2012)